HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. develops universal viral vector technologies for the prevention and cure of infectious diseases and cancers, focusing on eliciting potent immune responses.
Classification
Profile
Funding
Compliance
Signals
Fundraising & market
Prevention and cure for tumors or infectious diseases using a universal, patent-protected platform of engineered viruses that elicit potent neutralizing antibodies and T cell responses.
Pharmaceutical and biotech companies seeking partners for immuno-oncology or infectious disease therapies, specifically targeting HPV-associated cancers.
Licensing and asset sales, evidenced by the sale of next-generation therapeutic cancer vaccine programs to NeoTrail Therapeutics.
Direct business development and strategic partnerships, as demonstrated by the direct sale of assets to another company.
NeoTrail Therapeutics, which acquired HOOKIPA's next-generation therapeutic cancer vaccine programs.
Research and development costs associated with engineering viruses and advancing clinical applications like HB-201 and HB-202.
Patent-protected family of engineered viruses, TheraT and Vaxwave platforms, and expertise from founders including Nobel Laureate Prof. Rolf Zinkernagel.
Developing TheraT and Vaxwave platforms, engineering viruses to target specific antigens like E7E6, and conducting clinical trials for cancer treatments.
B2B strategic transactions and partnerships, focused on transferring proprietary technology and assets to industry clients.
Competes in the immuno-oncology space with engineered virus therapies targeting HPV-associated head and neck cancers, differentiating via LCMV-based viral backbones.
Need for effective prophylaxis or therapy for HPV-associated head and neck cancers and other infectious diseases or tumors.
- Monetise the platform via non-exclusive licensing - Instead of full asset sales, retain equity upside by offering tiered, royalty-based l
Liquidity vs. Growth Trade-off - The recent asset sales provide short-term cash but shrink the pipeline, limiting long-term valuation unless · Regulatory Risk Mitigation - By focusing on early-stage IND-ready programs and partnering for later-stage development, Hookipa can offload c · Ecosystem Positioning - Positioning as a “platform-provider” rat
- Recent asset-sale disclosures (Gilead & NeoTrail) are corroborated by SEC filings and multiple reputable biotech news outlets (FierceBiot
No investors recorded yet.